View : 125 Download: 0

Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy

Title
Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy
Authors
Lee H.B.Noh H.Seo J.Y.Yu M.R.Ha H.
Ewha Authors
하헌주
SCOPUS Author ID
하헌주scopus
Issue Date
2007
Journal Title
Kidney International
ISSN
0085-2538JCR Link
Citation
vol. 72, no. SUPPL. 106, pp. S61 - S66
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy. © 2007 International Society of Nephrology.
DOI
10.1038/sj.ki.5002388
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE